{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"OptiLight in the Dry Eye Practice with Arthur Benjamin, MD","description":"In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more. Intro :37 Welcome to another episode of Eye Care insider :51 About Arthur Benjamin, MD 1:02 I wonder if you could talk about your training and what you currently do now? 1:39 Could you talk about what you\u2019ve seen throughout the years and what you\u2019ve seen in the trends in dry eye and how it has expanded in the population? 2:56 What is your current algorithm for someone with dry eye? How do you manage that? 5:01 Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00 With the OptiLight treatment option \u2026 what do you tell patients? What should they be expecting? 9:54 I recently saw that there\u2019s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54 What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07 What a fascinating discussion 17:43 Any last words? 17:55 Outro 18:09 Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein\/Doheny Eye Institute at UCLA\u2019s Geffen School of Medicine and is in private practice at Benjamin Eye Institute.   We\u2019d love to hear from you! Send your comments\/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant\/research support from Alimera Sciences, Allergan\/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan\/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock\/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures. ","author_name":"Eye Care Insider","author_url":"https:\/\/www.healio.com","html":"